Helix BioPharma Completes $1.9M Private Placement
Company Announcements

Helix BioPharma Completes $1.9M Private Placement

Helix Biopharma Corp. (TSE:HBP) has released an update.

Helix BioPharma Corp., a Toronto-based clinical-stage biopharmaceutical company, has successfully completed a private placement of common shares, raising CAD$1.9 million to bolster working capital. The offering involved the sale of over 12 million shares at $0.15 each, subject to a four-month hold period and TSX final approval. The funds will advance the company’s innovative immune-oncology therapies and proprietary DOS47 platform.

For further insights into TSE:HBP stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskHelix BioPharma Announces Share Consolidation Plan
TipRanks Canadian Auto-Generated NewsdeskHelix BioPharma Secures Funding Through Shares
TipRanks Canadian Auto-Generated NewsdeskHelix BioPharma’s Financial Update Clears Regulatory Hurdle
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App